TLSI Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

12.81M

+55.01%

-0.123

-69.29%

14.30M

+55.94%

-0.070

-82.05%

16.05M

+43.13%

-0.040

-85.19%

Estimates Revision

The market is revising Downward the revenue expectations for TriSalus Life Sciences, Inc. (TLSI) for FY2025, with the revenue forecasts being adjusted by -1.14% over the past three months. During the same period, the stock price has changed by 31.22%.

Revenue Estimates for FY2025

Revise Downward

-1.14%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+75.73%

In Past 3 Month

Stock Price

Go Up

+31.22%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast TLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSI is 11.60 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

10.00

Averages

11.60

High

16.00

Current: 0.000

Low

10.00

Averages

11.60

High

16.00

Canaccord

William Plovanic

Buy

upgrade

$11 -> $12

2025-12-17

Reason

Canaccord

William Plovanic

Price Target

$11 -> $12

2025-12-17

upgrade

Buy

Reason

Canaccord analyst William Plovanic raised the firm's price target on TriSalus Life Sciences to $12 from $11 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.

Canaccord Genuity

William Plovanic

Strong Buy

Maintains

$11

2025-03-28

Reason

Canaccord Genuity

William Plovanic

Price Target

$11

2025-03-28

Maintains

Strong Buy

Reason

Roth MKM

Jason Wittes

Strong Buy

Reiterates

$11

2025-01-24

Reason

Roth MKM

Jason Wittes

Price Target

$11

2025-01-24

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for TriSalus Life Sciences Inc (TLSI.O) is -23.51, compared to its 5-year average forward P/E of -4.47. For a more detailed relative valuation and DCF analysis to assess TriSalus Life Sciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.47

Current PE

-23.51

Overvalued PE

1.20

Undervalued PE

-10.14

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-10.60

Current EV/EBITDA

-102.01

Overvalued EV/EBITDA

12.22

Undervalued EV/EBITDA

-33.43

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

3.20

Current PS

5.08

Overvalued PS

6.51

Undervalued PS

-0.11

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

TLSI News & Events

Events Timeline

No data

News

9.0

2025-08-11Newsfilter

TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique

8.5

2025-07-24Newsfilter

TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock

8.5

2025-06-23Newsfilter

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

People Also Watch

Frequently Asked Questions

What is TriSalus Life Sciences Inc (TLSI) stock price today?

The current price of TLSI is 5.8 USD — it has decreased -5.54 % in the last trading day.

What is TriSalus Life Sciences Inc (TLSI)'s business?

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.

What is the price predicton of TLSI Stock?

What is TriSalus Life Sciences Inc (TLSI)'s revenue for the last quarter?

TriSalus Life Sciences Inc revenue for the last quarter amounts to 11.57M USD, increased 57.38 % YoY.

What is TriSalus Life Sciences Inc (TLSI)'s earnings per share (EPS) for the last quarter?

TriSalus Life Sciences Inc. EPS for the last quarter amounts to -0.96 USD, increased 700.00 % YoY.

What changes have occurred in the market's expectations for TriSalus Life Sciences Inc (TLSI)'s fundamentals?

How many employees does TriSalus Life Sciences Inc (TLSI). have?

TriSalus Life Sciences Inc (TLSI) has 110 emplpoyees as of January 10 2026.

What is TriSalus Life Sciences Inc (TLSI) market cap?

Today TLSI has the market capitalization of 289.79M USD.